NCT07151339

Brief Summary

Tertiary prevention program for women with preeclampsia, HELLP syndrome, kidney disease and pregnancy or associated conditions, including founding of a biobank. (Observational study since no interference with regular path of treatment suggested in national and international guidelines)

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
55mo left

Started Nov 2024

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress25%
Nov 2024Nov 2030

Study Start

First participant enrolled

November 1, 2024

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

August 20, 2025

Completed
14 days until next milestone

First Posted

Study publicly available on registry

September 3, 2025

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2029

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2030

Last Updated

September 3, 2025

Status Verified

August 1, 2025

Enrollment Period

5 years

First QC Date

August 20, 2025

Last Update Submit

August 28, 2025

Conditions

PreeclampsiaHELLP SyndromeEclampsiaKidney Disease

Keywords

cardiovascular preventionpreeclampsiapregnancy

Outcome Measures

Primary Outcomes (1)

  • Pulse wave velocity

    12 months

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility Detailswomen during pregnancy
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

women with preeclampsia/HELLP syndrome/kidney disease during pregnancy

You may qualify if:

  • older than 18 yrs
  • diagnosed preeclampsia, HELLP syndrome or kidney disease durig pregnancy

You may not qualify if:

  • unable for informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Schleswig- Holstein

Kiel, 24105, Germany

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Blood, urine, stool

MeSH Terms

Conditions

Pre-EclampsiaHELLP SyndromeEclampsiaKidney Diseases

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-InducedPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrologic DiseasesFemale Urogenital DiseasesMale Urogenital Diseases

Central Study Contacts

Laura K Sievers, MD

CONTACT

+49 431 500 23001Laura.Rakow@uksh.de

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
12 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 20, 2025

First Posted

September 3, 2025

Study Start

November 1, 2024

Primary Completion (Estimated)

November 1, 2029

Study Completion (Estimated)

November 1, 2030

Last Updated

September 3, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations

DE(1)